Glow study: MRD outcomes after fixed-duration Ibr+Ven versus Clb+O for first-line treatment of CLL in elderly or unfit patients
Glow study: MRD outcomes after fixed-duration Ibr+Ven versus Clb+O for first-line treatment of CLL in elderly or unfit patients
Clinical utility of molecular tumour profiling in breast cancer
Lenalidomide and rituximab as front-line chemo-free therapy for elderly frail patients with diffuse large B-cell lymphoma.
Antibody and T-cell responses to COVID-19 vaccination in myeloproliferative neoplasm patients
Allogeneic CAR-T PBCAR0191 with intensified lymphodepletion is highly active in pts with relapsed/refractory B-cell malignancies
Concurrent pembrolizumab with AVD for untreated classical Hodgkin lymphoma
Latest in advanced endometrial cancer
OncoAlert and ecancer weekly round up for November 29th - December 5th, 2021
Post-HSCT management of ALL - Adult ALL perspective
Latest in diagnostics in EGFR mutated NSCLC
The Lancet Commission on women and cancer
Palliative care and strategies for screening and early detection in Africa